Bayer's Farxiga rival Kerendia scores long-awaited kidney and heart disease nod for Type 2 diabetes patients

Bayer is marking its return to the U.S. cardiovascular arena with its drug finerenone to treat not just kidney disease in Type 2 diabetes patients, but also heart disease. Yet, questions still swirl over how well the company will fare against dominant therapies from AstraZeneca and Johnson & Johnson.